Shortcomings in the development of anti‑SARS-CoV-2 drugs: prioritizing medicinal chemistry efforts toward RdRp, 3CLpro, and PLpro inhibitors

Medicine in Drug Discovery · Published 2025-10-26 · DOI 10.1016/j.medidd.2025.100236

Free full text

Authors being retrieved — see the publisher record. https://doi.org/10.1016/j.medidd.2025.100236

Abstract

DOAJ holds no abstract for this record.

Read the article at the publisher →

Publication details

Year

2025

Related articles

• Leveraging network pharmacology for drug discovery: Integrative approaches and emerging insights · Medicine in Drug Discovery · 2025 · Same journal
• A rapid at-line LC-QTOF-MS/MS based targeting and guided isolation approach uncovers 2-methoxy-1,4-naphthoquinone from Impatiens balsamina Linn. as an anti-Malassezia agent · Medicine in Drug Discovery · 2026 · Same journal
• Duration of tenofovir disoproxil fumarate treatment and a rapid eGFR decline in a retrospective cohort of people living with HIV infection · Medicine in Drug Discovery · 2026 · Same journal
• Phenanthrene and dihydrophenanthrene derivatives from Vanda curvifolia with cytotoxic activity against glioblastoma cells · Medicine in Drug Discovery · 2026 · Same journal
• Enhancing the therapeutic potential of plumbagin in breast cancer via advanced nanomedicine approaches · Medicine in Drug Discovery · 2026 · Same journal
• 3D printing in drug delivery: emerging technologies, clinical translation, and the future of personalized medicine · Medicine in Drug Discovery · 2025 · Same journal
• Bacterial-based drug delivery systems: A new way to combat infectious disease · Medicine in Drug Discovery · 2025 · Same journal
• Fluoxetine promotes lysosome biogenesis via regulation of a RIOK2-TFEB axis · Medicine in Drug Discovery · 2025 · Same journal
• Determine interaction affinity changes of the SUMO E1 activating enzymes during SUMO activation using qFRET technology · Medicine in Drug Discovery · 2025 · Same journal
• Toward peptide-based protein replacement in fragile X syndrome: Evaluating the N-tat strategy · Medicine in Drug Discovery · 2025 · Same journal